On August 7, 2024, Marpai, Inc., a technology platform company specializing in healthcare solutions for self-funded employer health plans, reported its financial results for the second quarter of 2024. The company, which is listed on the OTCQX Market under the symbol MRAI, disclosed a net revenue of approximately $7.2 million for the quarter, marking a 28% decrease from the same period in the previous year. Operating expenses for the quarter were $14.3 million, including a significant charge for the impairment of goodwill and intangibles amounting to $7.6 million. This resulted in an operating loss of $12.3 million and a net loss of $13.0 million, or ($1.23) per share. Despite the losses, CEO Damien Lamendola expressed optimism about the company's progress towards profitability and highlighted a strong sales pipeline for Q1 2025. Marpai's President, John Powers, also noted improvements in customer service metrics and claim processing indicators. The company plans to hold a webcast on August 8, 2024, to discuss these results in more detail.

On August 7, 2024, Marpai, Inc., a technology platform company specializing in healthcare solutions for self-funded employer health plans, reported its financial results for the second quarter of 2024. The company, which is listed on the OTCQX Market under the symbol MRAI, disclosed a net revenue of approximately $7.2 million for the quarter, marking a 28% decrease from the same period in the previous year. Operating expenses for the quarter were $14.3 million, including a significant charge for the impairment of goodwill and intangibles amounting to $7.6 million. This resulted in an operating loss of $12.3 million and a net loss of $13.0 million, or ($1.23) per share. Despite the losses, CEO Damien Lamendola expressed optimism about the company's progress towards profitability and highlighted a strong sales pipeline for Q1 2025. Marpai's President, John Powers, also noted improvements in customer service metrics and claim processing indicators. The company plans to hold a webcast on August 8, 2024, to discuss these results in more detail.